Overall, the non-canonical NF-κB pathway plays a crucial role in driving immune dysregulation and inflammation in SLE and more research is required to explore its capabilities as a possible therapeutic target in treatment this complex autoimmune disease. This evidence concerns the gene NFKB1 and autoimmune disease.